Crossmark

Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target

Published Online: 2020-03-19

Published Print: 2020-07

Authors

Farschtschi, Said https://orcid.org/0000-0002-3596-5932
Kluwe, Lan https://orcid.org/0000-0001-9919-4551
Park, Su-Jin

Oh, Su-Jun

Mah, Nancy

Mautner, Victor-Felix

Kurtz, Andreas https://orcid.org/0000-0003-3301-6546
Funding

Funding for this research was provided by:

Deutsche Krebshilfe (110588)
License Information

Text and Data Mining valid from 2020-03-19

Version of Record valid from 2020-03-19
More Information

Article History

Received: 13 August 2019

Accepted: 10 March 2020

First Online: 19 March 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: The study was approved by the internal review board (Ethics Committee of the Ärztekammer Hamburg Number OB-089/04) and performed in full accordance with the Declaration of Helsinki.

: Written informed consent was obtained from all study participants.

Document is current